Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitami… Read more
Sunny Pharmtech Inc. (6676) - Total Liabilities
Latest total liabilities as of June 2025: NT$599.02 Million TWD
Based on the latest financial reports, Sunny Pharmtech Inc. (6676) has total liabilities worth NT$599.02 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sunny Pharmtech Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Sunny Pharmtech Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sunny Pharmtech Inc. Competitors by Total Liabilities
The table below lists competitors of Sunny Pharmtech Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Michigan Financial Corporation
PINK:EFIN
|
USA | $451.64 Million |
|
BYC Co Ltd
KO:001465
|
Korea | ₩176.08 Billion |
|
Hyundai Hcn
KO:126560
|
Korea | ₩60.16 Billion |
|
Morn Sun Feed Mill Corp
TWO:1240
|
Taiwan | NT$631.07 Million |
|
Patrangsit Healthcare Group Public Company Limited
BK:PHG
|
Thailand | ฿348.14 Million |
|
Bastei Lübbe AG
XETRA:BST
|
Germany | €46.33 Million |
|
Sierra Madre Gold and Silver Ltd
PINK:SMDRF
|
USA | $12.17 Million |
|
Pullup Entertainment Société anonyme
PA:ALPUL
|
France | €231.23 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Sunny Pharmtech Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunny Pharmtech Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunny Pharmtech Inc. (2019–2024)
The table below shows the annual total liabilities of Sunny Pharmtech Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$540.68 Million | +5.51% |
| 2023-12-31 | NT$512.44 Million | -22.40% |
| 2022-12-31 | NT$660.32 Million | +41.02% |
| 2021-12-31 | NT$468.26 Million | +2.87% |
| 2020-12-31 | NT$455.21 Million | -3.53% |
| 2019-12-31 | NT$471.84 Million | -- |